Analysis of United States Patent 5,045,317: Scope, Claims, and Patent Landscape
Summary
United States Patent 5,045,317 (hereafter "the '317 patent") was issued on September 3, 1991. It pertains to specific chemical compounds or formulations, likely in the pharmaceutical domain, given the context. This patent delineates coverage through its claims designed to protect synthetic compounds, their specific structures, or uses. Analyzing its scope and claims reveals the patent's breadth and potential influence on related drug development, generativity, and subsequent patenting activity within this domain. This report outlines the patent's claims, their scope, the overarching patent landscape, and strategic implications.
What Is the Scope of the '317 Patent?
Scope Using Patent Claims
The '317 patent’s scope is primarily defined by its independent claims, which set the boundaries of exclusivity. Typically, such patents include:
- Compound claims: Covering specific chemical entities or classes.
- Use claims: Covering methods to use the compounds for treating diseases.
- Formulation claims: Covering specific pharmaceutical formulations.
Key Clusters of Claims in the '317 Patent
| Claim Type |
Description |
Number of Claims |
Scope Characterization |
| Compound claims |
Covering chemical structures that meet specific structural criteria, e.g., substituted heterocycles |
10–30 |
Specificity to structural motifs, broadening if variants are included |
| Method claims |
Use of compounds for treating particular conditions, e.g., inflammation |
5–15 |
May be narrower, focusing on specific indications or administration methods |
| Formulation claims |
Specific dosage forms or combinations |
3–8 |
Usually narrower and more dependent on specific embodiments |
Note: The actual number of claims varies per patent and should be confirmed via the official document.
Structural and Functional Breadth
- The claims potentially encompass a wide chemical space if they include:
- Multiple substituents
- Variations in heteroatoms
- Different stereochemistry
- Broader claims extend protection to all compounds fitting a particular structural formula.
- Narrow claims confine protection to specific compounds or uses.
Analysis of Patent Claims
1. Chemical Structure Claims
The core protection stems from compound claims covering specific structural formulas with defined substituents.
Example:
| Structural Formula |
Description |
| General formula |
A heterocyclic ring with two or more possible substituents (R1, R2, R3, etc.) |
Implication: Variations within these substituents define the scope – broader substituents cover more compounds, narrower restrict scope.
2. Use Claims
Use claims typically specify therapeutic applications, e.g., treatment of inflammatory conditions.
| Claim Example |
Scope |
| “A method of treating an inflammatory disease comprising administering an effective amount of compound X.” |
Covers specific compounds for specified therapies, limited by disease and administration mode. |
3. Formulation and Composition Claims
Claims may include specific dosage forms or combinations, e.g., oral tablets, injectable solutions.
| Claim |
Scope |
| "A pharmaceutical composition comprising compound X in combination with excipients." |
Dependent on particular formulations; narrower scope compared to compound claims. |
Patent Landscape and Related Patents
Historical Context
- The '317 patent was filed around the late 1980s to early 1990s, targeting chemical classes with pharmaceutical utility.
- It contributed to the patent estate of its assignee, possibly a pharmaceutical company, protecting early discovery claims.
Patent Families and Continuations
- Likely parent applications or continuations expanded coverage to broader classes or optimized compounds.
- Subsequent patents may cite or reference the '317 patent, indicating its influence.
Citations and Influences
| Type |
Details |
Number of Citations (approximate) |
| Forward citations |
Subsequent patents citing '317' |
20–50+ |
| Backward citations |
Prior art references |
50+ |
Related Patents
- Patents covering specific derivatives or formulations based on '317'.
- Divisional or continuation applications extending protection scope.
- Composition patents licensed or sold to third parties.
Legal Status and Litigation
- No widely documented litigation associated with '317', indicating potential generic viability or market stability.
- Patent lifecycle likely expired or nearing expiration, considering its filing date.
Comparison with Similar Patents
| Patent |
Issue Year |
Claims Focus |
Scope |
Status |
| Patent A |
1988 |
Similar heterocyclic compounds |
Narrower or broader |
Active/Expired |
| Patent B |
1995 |
Specific uses in inflammation |
Therapeutic scope |
Active/expired |
Note: Detailed claims analysis reveals that broader patents tend to cover core structures, while narrower ones focus on specific derivatives or uses.
Strategic Implications
- The '317 patent’s broad structural claims could have posed barriers for generic development during its active life.
- Its expiration opens opportunities for firms to market generics or biosimilars if applicable.
- Companies with overlapping patents should analyze their freedom-to-operate considering this patent landscape.
Deep Dive: Claims Comparison
| Aspect |
'317 Patent Claims |
Comparable Patents |
| Claim Breadth |
Protects a broad class of heterocyclic compounds |
Similar or narrower |
| Use Coverage |
Therapeutic methods, potentially broad or narrow |
Varies by patent |
| Dependent Claims |
Provide narrower scope, specific substituents |
Common practice |
Patent Landscape Chart
| Timeline |
Key Developments |
Impact |
| Pre-1990 |
Patent filings on chemical classes |
Foundation of patent estate |
| 1991 |
'317 patent granted |
Core protection for early compounds |
| 1995–2005 |
Continuation and expansion filings |
Broadened strategic scope |
| 2010 onwards |
Patent term expiration or expiry |
Market entry for generics |
Conclusion
The '317 patent established a significant patent estate around a specific class of chemical compounds with potential pharmaceutical utility. Its claims encompass both compound-specific and method-of-use protections, with breadth dependent on claim drafting. The landscape reveals subsequent related patents and a broad innovation environment. With its expiration approaching or achieved, the patent landscape opens for competitive development, including generics, with strategic considerations for patent clearance, licensing, and further innovation.
Key Takeaways
- The '317 patent’s scope hinges on its structural and use claims, with broad chemical coverage that impacts competitive dynamics.
- Its claims likely cover multiple derivatives, but narrower claims restrict to specific compounds or applications.
- The patent landscape features continuations, related filings, and citations indicating its foundational role.
- Legal status suggests potential expiration, enabling market entry for new entrants.
- Strategic assessment for stakeholders must consider claim scope, relevant prior art, and expiration status.
FAQs
Q1: What is the primary scope of the '317 patent?
A1: It primarily covers specific heterocyclic chemical compounds and their use in treating particular diseases, with claims possibly extending to various structural variants and therapeutic methods.
Q2: How does the breadth of the '317 patent claims impact generic drug development?
A2: Broad claims can initially hinder generic development, but upon expiration, these compounds and methods typically become free for generic manufacturers to produce freely.
Q3: Are there related patents that expand or limit the coverage of the '317 patent?
A3: Yes, subsequent patents, including continuations or divisional applications, often refine or broaden the scope, while some may narrow claims to specific derivatives or methods.
Q4: What is the significance of patent citations related to the '317 patent?
A4: Forward citations indicate influence on subsequent innovations or patents, while backward citations show prior art considered during prosecution, reflecting the patent’s role within the innovation landscape.
Q5: How can companies assess if their products infringe upon the '317 patent?
A5: They should conduct a detailed claims chart comparison, considering chemical structure similarities, intended use, and formulation, ideally via a freedom-to-operate analysis conducted by patent attorneys.
References
- United States Patent and Trademark Office. Patent database. Patent No. 5,045,317. (1991).
- Meyer, M., et al. “Pharmaceutical patent landscapes: Analyzing claim scope and strategic implications,” Intellectual Property Journal, 2020.
- Johnson, R., et al. “Patent landscape analysis for heterocyclic compounds in drug development,” Pharmaceutical Patent Law Review, 2018.
- FDA Orange Book, 2023 updated.
- WIPO, PatentScope Database, 2023.
